Showing 4441-4450 of 6036 results for "".
- TearRestore’s Thermal Mask & HylaWipe Tea Tree Eyelid Wipes Now Available at Targethttps://modernod.com/news/tearrestores-thermal-mask-hylawipe-tea-tree-eyelid-wipes-now-available-at-target/2481508/TearRestore announced that its Thermal Mask and Eyelid Wipes will now be available at Target stores nationwide and at Target.com. The Thermal Mask and Eye Wipe offer alternative options to artificial tears and are designed to directly address the
- Abionyx Pharma Announces Its Strategy in Ophthalmologyhttps://modernod.com/news/abionyx-pharma-announces-its-strategy-in-ophthalmology/2481506/France-based Abionyx Pharma announced announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. "The acquisition of IRIS Pharma, one of the world leaders in contract research in ophthalmology,
- Kala Pharmaceuticals Appoints Francis Mah, MD, as Chief Medical Advisorhttps://modernod.com/news/kala-pharmaceuticals-appoints-francis-mah-md-as-chief-medical-advisor/2481501/Kala Pharmaceuticals announced the appointment of Francis Mah, MD, as Chief Medical Advisor. In this new role, Dr. Mah will provide support for Kala’s clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in
- Andreas C. Kühnel Appointed as Geschäftsführer Managing Director at VSY Biotechnologyhttps://modernod.com/news/andreas-c-kuhnel-appointed-as-geschaftsfuhrer-managing-director-at-vsy-biotechnology/2481500/VSY Biotechnology has announced the appointment of Andreas Christoph Kühnel as its new Managing Director. In this new role, Mr. Kühnel will be responsible for developing and expanding VSY Biotechnology’s operations on a global scale. Mr. Kühnel brings expertise and
- Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for RP and LCA Gene Therapyhttps://modernod.com/news/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-12-clinical-trial-for-rp-and-lca-gene-therapy/2481499/Ocugen announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 phase 1/2 trial. OCU400 is a gene therapy candidate for retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). “This approval moves us one step closer in our efforts to bri
- Study: Reduced Oxygen Transport to the Retina Contributing to Damage to the Fine Blood Vessels Causes Diabetic Retinopathyhttps://modernod.com/news/study-reduced-oxygen-transport-to-the-retina-owing-to-damage-to-the-fine-blood-vessels-causes-diabetic-retinopathy/2481492/Researchers in Austria have now found evidence for a previously suspected connection: reduced oxygen transport to the retina contributes to damage to the fine blood vessels, causing diabetic retinopathy. A common complication of diabetes, this retinal damage can ultimately lead to blind
- Aurion Biotech Receives Approval in Japan for First Allogeneic Cell Therapy to Treat Corneal Endothelial Diseasehttps://modernod.com/news/aurion-biotech-receives-approval-in-japan-for-first-allogeneic-cell-therapy-to-treat-corneal-endothelial-disease/2481486/Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel cell therapy, Vyznova, for the treatment of bullous keratopathy of the cornea. The company believes this is the first regulatory approval in the world fo
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congresshttps://modernod.com/news/nicox-announces-presentations-of-additional-ncx-470-data-at-the-upcoming-world-glaucoma-congress/2481481/Nicox SA announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC), which will be held from June 28 to July 1, 2023 in Rome, Italy. Details of the presentations: Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donati
- NovaBay Pharmaceuticals Launches Avenova Eye Health Support to Comfort Dry Eyes and Promote Eye Healthhttps://modernod.com/news/novabay-pharmaceuticals-launches-avenova-eye-health-support-to-comfort-dry-eyes-and-promote-eye-health/2481480/NovaBay Pharmaceuticals announced the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and natural triglyceride omega-3 oils, designed to comfort dry eyes and s